134 related articles for article (PubMed ID: 3646455)
21. Simultaneous isolation of simian foamy virus and HTLV-III/LAV from chimpanzee lymphocytes following HTLV-III or LAV inoculation.
Nara PL; Robey WG; Arthur LO; Gonda MA; Asher DM; Yanagihara R; Gibbs CJ; Gajdusek DC; Fischinger PJ
Arch Virol; 1987; 92(1-2):183-6. PubMed ID: 2432853
[TBL] [Abstract][Full Text] [Related]
22. Acquired immune deficiency syndrome (AIDS)--recommendations of IMAP.
International Planned Parenthood Federation IPPF. International Medical Advisory Panel IMAP
IPPF Med Bull; 1986 Jun; 20(3):3-4. PubMed ID: 12268332
[TBL] [Abstract][Full Text] [Related]
23. Acquired immunodeficiency syndrome: meeting of the WHO Collaborating Centres on AIDS.
Centers for Disease Control (CDC)
MMWR Morb Mortal Wkly Rep; 1985 Nov; 34(44):678-9. PubMed ID: 3932833
[TBL] [Abstract][Full Text] [Related]
24. [Correlation between serum p24 antigen and the isolation of human immunodeficiency virus (HIV) from the lymphocytes of subjects with HIV infection].
Angarano G; Fiore JR; Casalino C; Monno L; Esposito M; Pastore G
Boll Soc Ital Biol Sper; 1988 Aug; 64(8):739-45. PubMed ID: 3214574
[No Abstract] [Full Text] [Related]
25. AIDS-related benign lymphadenopathy and malignant lymphoma: clinical aspects and virologic interactions.
Abrams DI; Kaplan LD; McGrath MS; Volberding PA
AIDS Res; 1986 Dec; 2 Suppl 1():S131-40. PubMed ID: 3828009
[TBL] [Abstract][Full Text] [Related]
26. Immune status of drug abusers.
Fuchs D; Hausen A; Reibnegger G; Schönitzer D; Unterweger B; Blecha HG; Hengster P; Rössler H; Schulz T; Werner ER
Cancer Detect Prev Suppl; 1987; 1():535-41. PubMed ID: 3480066
[TBL] [Abstract][Full Text] [Related]
27. Epidemiological evidence that HTLV-III is the AIDS agent.
Goedert JJ; Gallo RC
Eur J Epidemiol; 1985 Sep; 1(3):155-9. PubMed ID: 2945735
[TBL] [Abstract][Full Text] [Related]
28. Isolation frequency and growth properties of HIV-variants: multiple simultaneous variants in a patient demonstrated by molecular cloning.
von Briesen H; Becker WB; Henco K; Helm EB; Gelderblom HR; Brede HD; Rübsamen-Waigmann H
J Med Virol; 1987 Sep; 23(1):51-66. PubMed ID: 2890703
[TBL] [Abstract][Full Text] [Related]
29. A stage model of HTLV-III LAV infection in intravenous drug users.
Des Jarlais DC; Friedman SR; Spira TJ; Zolla-Pazner S; Marmor M; Holzman R; Mildvan D; Yancovitz S; Mathur-Wagh U; Garber J
NIDA Res Monogr; 1986; 67():328-34. PubMed ID: 3018574
[No Abstract] [Full Text] [Related]
30. HTLV-III expression in infected lymph nodes and relevance to pathogenesis of lymphadenopathy.
Biberfeld P; Chayt KJ; Marselle LM; Biberfeld G; Gallo RC; Harper ME
Am J Pathol; 1986 Dec; 125(3):436-42. PubMed ID: 3642987
[TBL] [Abstract][Full Text] [Related]
31. Predominance of HIV-1 among patients with AIDS and AIDS-related complex in Ghana.
Brandful JA; Ampofo WK; Apeagyei FA; Asare-Bediako K; Osei-Kwasi M
East Afr Med J; 1997 Jan; 74(1):17-20. PubMed ID: 9145571
[TBL] [Abstract][Full Text] [Related]
32. [Thrombopenic purpura in a group of addicts addicted to parenteral drugs with anti-HTLV-III/LAV antibodies and inversion of the T-helper/T-suppressor cell quotient].
Aguilar Ligorti E; Guix García J; Ample Guillén I; Balaguer Martínez JV; Marugán de la Concha I; García-Conde Bru J
Sangre (Barc); 1986; 31(4):401-10. PubMed ID: 2947340
[No Abstract] [Full Text] [Related]
33. Activated T cells in addition to LAV/HTLV-III infection: a necessary precondition for development of AIDS.
Fuchs D; Hausen A; Hoefler E; Schönitzer D; Werner ER; Dierich MP; Hengster P; Reibnegger G; Schulz T; Wachter H
Cancer Detect Prev Suppl; 1987; 1():583-7. PubMed ID: 3500785
[TBL] [Abstract][Full Text] [Related]
34. Screening for seroprevalence of HTLV-III/HIV infection in high risk groups in Delhi.
Kumari S; Rai A; Chattopadhya D; Khare S; Ichhpujani RL; Sehgal PN
J Commun Dis; 1986 Jun; 18(2):77-80. PubMed ID: 3805683
[TBL] [Abstract][Full Text] [Related]
35. The LAV/HTLV-III screening in Copenhagen. Epidemiological results from four clinics over the period 1 July 1984 to 1 April 1985.
Kolby P; Pedersen C; Sindrup JH; Gaub J; Arendrup M; Gerstoft J
Dan Med Bull; 1986 Oct; 33(5):268-70. PubMed ID: 3780322
[TBL] [Abstract][Full Text] [Related]
36. [Prevalence and morbidity of HTLV-III/LAV infection in homosexuals and parenteral drug addicts (up-date 1985)].
Cárcaba V; Fernández-León A; Cartón JA; Palacio V
Med Clin (Barc); 1987 Jan; 88(3):123-4. PubMed ID: 3821277
[No Abstract] [Full Text] [Related]
37. [Ultrastructural markers in LAV-HTLV III virus infection: study of the rectal mucosa in 16 patients].
Bruneval P; Leport C; Tricottet V; Leport J; Bloch F; Vilde JL; Camilléri JP
Gastroenterol Clin Biol; 1986 Apr; 10(4):328-33. PubMed ID: 3721115
[TBL] [Abstract][Full Text] [Related]
38. [Viral particles identical to HTLV-I in lymphocyte cultures of an asymptomatic woman whose serum contained antibodies against HTLV-I and HTLV-III/LAV-I and LAV-II].
Cardoso EA; Terrinha AM; Nunes JF
Acta Med Port; 1988; 1(1):5-7. PubMed ID: 3207051
[No Abstract] [Full Text] [Related]
39. [Isolation of human immunodeficiency virus from Hungarian AIDS and ARC patients].
Nagy K; Jan A; Bánhegyi D; Várnai F
Orv Hetil; 1990 Apr; 131(17):895-8. PubMed ID: 2345635
[TBL] [Abstract][Full Text] [Related]
40. Antibodies anti-HTLV III and lymphocyte subsets of high risk subjects.
Ripa S; Mignini F; Anichini M; Casprini P; Prenna M
Boll Ist Sieroter Milan; 1987; 66(2):101-5. PubMed ID: 3663335
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
